DPYD
DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oesophageal junction cancer.
Overview
Catalyses the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine. Also capable of degrading the chemotherapeutic drug 5-fluorouracil.
CIViC holds 4 clinical evidence items and 0 assertions across 4 variants, naming Fluorouracil, Capecitabine, Tegafur and Leucovorin. Open Targets scores its association with cancer at 0.68 (direct and indirect evidence; datatypes clinical 0.94, affected pathway 0.94, literature 0.87, genetic association 0.33, somatic mutation 0.23, animal model 0.38).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oesophageal junction cancer.
- 1 · What it is
DPYD (Dihydropyrimidine dehydrogenase [NADP(+)]) is an enzyme. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Head and neck squamous cell carcinoma and Gastric & gastro-oesophageal junction cancer.
- 2 · What goes wrong in cancer
Catalyses the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine.
- 3 · How drugs use it
No product in this corpus aims at DPYD yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
External identifiers
Sources: HGNC HGNC:3012 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q12882 (protein name, function text, keywords and locations (REST API)); CIViC gene DPYD (4 evidence items, 0 assertions, 4 variants; diseases: Cancer, Head And Neck Squamous Cell Carcinoma (GraphQL API, CC0)); Open Targets ENSG00000188641 (association with cancer (MONDO_0004992) 0.68; per-cancer scores at or above 0.5: gastric cancer 0.54 (GraphQL API, CC0))
Biology
Catalyses the reduction of uracil and thymine in the initial step of reductive pyrimidine catabolism, a pathway that yields beta-alanine from uracil and beta-aminoisobutyrate from thymine. Also capable of degrading the chemotherapeutic drug 5-fluorouracil. Location: Cytoplasm, cytosol (UniProt). Locus 1p21.3 (HGNC).
- Head and neck squamous cell carcinoma: CIViC evidence names this disease
- Gastric & gastro-oesophageal junction cancer: Open Targets association 0.54 with gastric cancer (MONDO_0001056)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.94; CIViC holds 4 clinical evidence items on its variants. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"DPYD" OR ABSTRACT:"DPYD" OR TITLE:"dihydropyrimidine dehydrogenase" OR ABSTRACT:"dihydropyrimidine dehydrogenase" OR TITLE:"Dihydropyrimidine dehydrogenase [NADP + ]" OR ABSTRACT:"Dihydropyrimidine dehydrogenase [NADP + ]" OR TITLE:"DHPDHase" OR ABSTRACT:"DHPDHase") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DPYD, not a curated reading list.